| Literature DB >> 30781445 |
Enis Nadia Md Yusof1,2, Muhammad A M Latif3, Mohamed I M Tahir4, Jennette A Sakoff5, Michela I Simone6,7, Alister J Page6, Abhi Veerakumarasivam8,9, Edward R T Tiekink10, Thahira B S A Ravoof11,12.
Abstract
Six new organotin(IV) compounds ofEntities:
Keywords: cytotoxic activity; dithiocarbazate; five-coordinate compounds; mechanistic studies; molecular docking; organotin(IV); single-crystal X-ray diffraction analysis; tridentate ONS Schiff bases
Mesh:
Substances:
Year: 2019 PMID: 30781445 PMCID: PMC6413231 DOI: 10.3390/ijms20040854
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Scheme 1Synthetic pathway for the formation of SBoVaH, S2MoVaH, and S4MoVaH.
Scheme 2Synthesis of organotin(IV) compounds.
Figure 1The thione (a) and thiol (b) tautomeric forms of the Schiff bases (R = o–CH3, S2MoVaH; p-CH3, S4MoVaH; R = H, SBoVaH).
Figure 2Molecular structures of the first independent molecules of (a) Me2Sn(S2MoVa), (b) Me2Sn(S4MoVa) and (c) Me2Sn(SBoVa) showing atom labelling schemes. (d) Overlay diagram of the two independent molecules of each of Me2Sn(S2MoVa), a (red image) and b (green), Me2Sn(S4MoVa), a (blue) and b (pink), and Me2Sn(SBoVa) a (yellow) and b (aqua) with the SnMe2 planes superimposed.
Figure 3Crystallographic diagrams for Me2Sn(S2MoVa): (a) Molecular structure of the second independent molecule, molecule b, (b) overlay diagram of molecules a (red image) and inverted-b (green) drawn so the SnC2 atoms of the Me2Sn moiety are overlapped and (c) a view of the supramolecular layer in the ab-plane (left image) and a view of the unit cell contents in projection down the a-axis with one layer highlighted in space-filling mode (right image). The C–H…O and C–H…π interactions are shown as orange and purple dashed lines, respectively.
Figure 4Crystallographic diagrams for Me2Sn(S4MoVa): (a) Molecular structure of the second independent molecule, molecule b, (b) overlay diagram of molecules a (blue image) and inverted-b (pink) drawn so the SnC2 atoms of the Me2Sn moiety are overlapped and (c) a view of the supramolecular dimer sustained by C–H…π (chelate) interactions (left image; non-participating hydrogen atoms have been omitted) and a view of the unit cell contents in projection down the a-axis. The C–H…O and C–H…π interactions are shown as orange and purple dashed lines, respectively.
Figure 5Crystallographic diagrams for Sn(SBoVa)Me2: (a) Molecular structure of the second independent molecule, molecule b, (b) overlay diagram of molecules a (yellow image) and b (aqua) drawn so the five-membered rings are overlapped and (c) supramolecular dimer sustained by edge-to-edge chelate ring…benzene interactions (upper image) between Sn1-containing molecules, supramolecular layer sustained by edge-to-edge π (chelate ring)…π (ethoxybenzene) and phenyl-C–H…π (methoxybenzene) interactions occurring between Sn2-containing molecules and a view of the unit cell contents in projection down the b-axis. The edge-to-edge π (chelate ring)…π (ethoxybenzene) and C–H…π interactions are shown as blue and purple dashed lines, respectively.
Selected geometric parameters (Å, °) for Me2Sn(S2MoVa), Me2Sn(S4MoVa) and Me2Sn(SBoVa).
| Parameter | Me2Sn(S2MoVa) | Me2Sn(S4MoVa) | Me2Sn(SBoVa) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Bond lengths | molecule a | molecule b | B3LYP | molecule a | molecule b | B3LYP | molecule a | molecule b | B3LYP |
| LanL2DZ/6-311G(d,p) | LanL2DZ/6-311G(d,p) | LanL2DZ/6-311G(d,p) | |||||||
| Sn–S1 | 2.545(2) | 2.542(2) | 2.576 | 2.5391(8) | 2.5309(7) | 2.566 | 2.5789(11) | 2.5607(10) | 2.590 |
| Sn–O1 | 2.092(6) | 2.102(6) | 2.085 | 2.090(2) | 2.214(2) | 2.078 | 2.103(3) | 2.093(3) | 2.078 |
| Sn–N2 | 2.188(6) | 2.192(6) | 2.285 | 2.223(2) | 2.088(2) | 2.232 | 2.194(3) | 2.205(3) | 2.226 |
| C1–S1 | 1.726(9) | 1.717(8) | 1.751 | 1.736(3) | 1.734(3) | 1.753 | 1.725(4) | 1.726(4) | 1.748 |
| C1–S2 | 1.744(8) | 1.747(8) | 1.772 | 1.752(3) | 1.757(3) | 1.771 | 1.771(4) | 1.763(4) | 1.783 |
| N1–N2 | 1.394(9) | 1.406(9) | 1.389 | 1.402(3) | 1.409(3) | 1.388 | 1.397(5) | 1.395(4) | 1.383 |
| C1–N1 | 1.304(11) | 1.273(10) | 1.293 | 1.289(4) | 1.287(4) | 1.293 | 1.298(5) | 1.291(5) | 1.296 |
| C(x)–N2 | 1.308(9) | 1.306(9) | 1.313 | 1.309(4) | 1.307(4) | 1.312 | 1.311(5) | 1.304(5) | 1.307 |
| Bond angles | |||||||||
| S1–Sn–O1 | 157.89(17) | 158.25(17) | 159.5 | 158.51(7) | 155.88(7) | 159.7 | 155.82(9) | 154.24(10) | 159.8 |
| S1–Sn–N2 | 77.35(18) | 76.94(18) | 77.6 | 77.33(7) | 77.78(6) | 77.8 | 76.70(9) | 77.13(8) | 77.3 |
| O1–Sn–N2 | 82.2(2) | 82.3(2) | 82.0 | 82.13(9) | 82.15(8) | 82.2 | 82.76(11) | 82.09(12) | 82.4 |
| C18–Sn–C(y) | 128.9(5) | 128.2(5) | 123.9 | 122.58(14) | 123.05(14) | 123.9 | 127.70(18) | 124.8(2) | 123.7 |
| S1–C1–S2 | 112.1(5) | 111.9(5) | 113.4 | 111.46(17) | 111.81(17) | 113.4 | 120.2(2) | 120.1(2) | 120.8 |
| S1–C1–N1 | 129.1(6) | 128.9(6) | 128.2 | 129.1(2) | 129.6(2) | 128.2 | 128.7(3) | 128.3(3) | 127.7 |
| S2–C1–N1 | 118.9(7) | 119.3(6) | 118.4 | 119.5(2) | 118.6(2) | 118.4 | 111.1(3) | 111.6(3) | 111.5 |
Figure 6Apoptosis detection through fluorescence microscopy. Cells were treated for 24 h with Ph2Sn(SBoVa) (0.58 µM), Ph2Sn(S2MoVa) (0.31 µM) and Ph2Sn(S4MoVa) (1.66 µM) and the negative control (DMSO) in complete media. After staining with Annexin V and PI, necrotic and apoptotic cells were detected by fluorescence microscopy (20×).
Summary of the in vitro cytotoxicity of the Schiff bases and their organotin(IV) compounds in several cell lines, determined by MTT assay and expressed as GI50 values with standard errors. (GI50 is the concentration at which cell growth is inhibited by 50% over 72 h).
| Compounds | Growth Inhibition Concentration, GI50 (µM) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EJ-28 | RT-112 | HT29 | U87 | MCF-7 | A2780 | H460 | A431 | Du145 | BE2-C | SJ-G2 | MIA | MCF10A | |
| S2MoVaH | 3.4 ± 0.47 | 4.6 ± 0.45 | 3.9 ± 0.71 | 4.3 ± 0.30 | 2.7 ± 0.21 | 3.2 ± 0.15 | 4.3 ± 0.12 | 3.8 ± 0.03 | 4.1 ± 0.09 | 3.1 ± 0.00 | 3.0 ± 0.09 | 4.9 ± 0.37 | 3.1 ± 0.07 |
| Ph2Sn(S2MoVa) | 0.35 ± 0.05 | 0.31 ± 0.05 | 1.8 ± 0.13 | 4.4 ± 1.7 | 1.4 ± 0.12 | 0.23 ± 0.01 | 2.8 ± 0.00 | 2.1 ± 0.09 | 1.7 ± 0.07 | 0.47 ± 0.05 | 0.84 ± 0.09 | 0.34 ± 0.02 | 1.2 ± 0.30 |
| Me2Sn(S2MoVa) | 2.5 ± 0.78 | 2.4 ± 0.77 | 2.7 ± 0.10 | 3.6 ± 0.23 | 3.1 ± 0.12 | 3.1 ± 0.06 | 3.3 ± 0.13 | 3.0 ± 0.03 | 3.9 ± 0.03 | 2.9 ± 0.03 | 2.5 ± 0.30 | 3.9 ± 0.07 | 3.0 ± 0.09 |
| S4MoVaH | 3.6 ± 0.44 | 3.2 ± 0.51 | 8.0 ± 3.5 | 3.9 ± 0.00 | 3.5 ± 0.00 | 3.1 ± 0.40 | 5.5 ± 0.73 | 4.2 ± 0.74 | 5.4 ± 0.23 | 3.6 ± 0.27 | 3.3 ± 0.87 | 11 ± 2.3 | 3.5 ± 0.23 |
| Ph2Sn(S4MoVa) | 3.1 ± 0.37 | 1.7 ± 0.49 | 0.87 ± 0.22 | 1.3 ± 0.40 | 0.82 ± 0.14 | 0.35 ± 0.07 | 1.9 ± 0.23 | 1.4 ± 0.38 | 1.5 ± 0.31 | 0.53 ± 0.01 | 1.0 ± 0.16 | 0.39 ± 0.03 | 1.1 ± 0.37 |
| Me2Sn(S4MoVa) | >5.0 | >5.0 | 6.9 ± 3.5 | 3.3 ± 0.18 | 3.3 ± 0.32 | 3.1 ± 0.63 | 4.7 ± 0.46 | 4.2 ± 0.34 | 4.2 ± 0.10 | 3.3 ± 0.23 | 3.1 ± 0.55 | 8.9 ± 1.30 | 3.3 ± 0.15 |
| SBoVaH | 3.1 ± 0.20 | 3.7 ± 0.57 | 2.2 ± 0.033 | 3.1 ± 0.26 | 2.5 ± 0.12 | 3.0 ± 0.06 | 3.3 ± 0.21 | 3.0 ± 0.15 | 3.4 ± 0.30 | 2.8 ± 0.20 | 2.4 ± 0.26 | 4.5 ± 0.25 | 3.0 ± 0.07 |
| Ph2Sn(SBoVa) | 0.32 ± 0.05 | 0.58 ± 0.29 | 1.2 ± 0.22 | 1.1 ± 0.39 | 0.90 ± 0.16 | 0.23 ± 0.03 | 2.2 ± 0.00 | 1.6 ± 0.07 | 1.4 ± 0.33 | 0.50 ± 0.05 | 0.74 ± 0.15 | 0.43 ± 0.04 | 1.3 ± 0.20 |
| Me2Sn(SBoVa) | 3.4 ± 0.30 | 2.4 ± 0.33 | 2.8 ± 0.15 | 4.5 ± 0.19 | 2.5 ± 0.21 | 3.2 ± 0.03 | 3.8 ± 0.10 | 3.2 ± 0.03 | 3.2 ± 0.13 | 2.7 ± 0.13 | 2.1 ± 0.12 | 5.0 ± 0.09 | 2.8 ± 0.41 |
| Cisplatin | 3.97 ± 0.48 | 3.56 ± 0.88 | 11.0 ± 2.0 | 4.0 ± 1.0 | 6.5 ± 0.8 | 1.0 ± 0.1 | 0.9 ± 0.2 | 2.4 ± 0.3 | 1.2 ± 0.1 | 1.9 ± 0.2 | 0.4 ± 0.1 | 8.0 ± 1.0 | nd |
GI50 (μM): (the colors indicate) = 0.1–0.99; = 1.0–9.9; = 10–100; = nd (not determined).
Figure 7Percent reactive oxygen species (ROS) production in RT-112 cells treated with (a) Ph2Sn(S2MoVa) (0.31 μM) (b) Ph2Sn(S4MoVa) (1.66 μM) for 24 h and stained with 1 mM DCFH-DA for 60 minutes at 37 °C. DMSO and H2O2 acted as negative and positive controls, respectively.
Figure 8(a) Electronic absorption spectra of (i) Ph2Sn(S2MoVa), (ii) Ph2Sn(S4MoVa) and (iii) Ph2Sn(SBoVa); (b) Plot of [DNA]/εa − εf vs. [DNA] for absorption titration of DNA with (i) Ph2Sn(S2MoVa), (ii) Ph2Sn(S4MoVa) and (iii) Ph2Sn(SBoVa). The arrow indicates the change in absorbance in tandem with increasing DNA concentration.
Binding constants (Kb), hypochromism (%), bathochromic shifts (nm) and Gibbs free energy (kJ mol−1) values for the interaction of organotin(IV) compounds with calf thymus DNA (CT-DNA).
| Compounds | Binding Constant (Kb) | Hypochromism, (%) | Bathochromism Shift (nm) | Gibbs Free Energy (kJ mol−1) |
|---|---|---|---|---|
| Ph2Sn(S2MoVa) | 6.21 × 105 | 41.06 | 6 | −33.1 |
| Me2Sn(S2MoVa) | 3.46 × 105 | 37.97 | 10 | −31.6 |
| Ph2Sn(S4MoVa) | 2.67 × 105 | 28.25 | 4 | −31.0 |
| Me2Sn(S4MoVa) | 4.15 × 105 | 43.72 | 7 | −32.1 |
| Ph2Sn(SBoVa) | 1.21 × 106 | 70.72 | 12 | −34.7 |
| Me2Sn(SBoVa) | 3.91 × 106 | 53.26 | 1 | −37.6 |
Molecular docking data for the organotin(IV) compounds with B-DNA (PDB ID: 1BNA) dodecamer d(CGCGAATTCGCG)2.
| Complex | Final Intermolecular Energy, kcal mol−1 | Final Total Internal Energy (2), kcal mol−1 | Torsional Free Energy (3), kcal mol−1 | Unbound System’s Energy [=(2)] (4), kcal mol−1 | Estimated Free Energy of Binding [(1) + (2) + (3) − (4)], kcal mol−1 | Estimated Free Energy of Binding, kJ mol−1 | ||
|---|---|---|---|---|---|---|---|---|
| vdW + Hbond + desolv. Energy | Electrostatic Energy | Total (1) | ||||||
| Ph2Sn(S2MoVa) | −11.46 | 0.00 | −11.47 | −2.19 | 1.79 | −2.19 | −9.68 | −40.50 |
| Me2Sn(S2MoVa) | −10.27 | −0.03 | −10.30 | 0.57 | 1.19 | −0.57 | −9.10 | −38.07 |
| Ph2Sn(S4MoVa) | −11.87 | 0.01 | −11.86 | −1.82 | 1.79 | −1.82 | −10.07 | −42.13 |
| Me2Sn(S4MoVa) | −10.84 | 0.00 | −10.83 | −0.53 | 1.19 | −0.53 | −9.64 | −40.33 |
| Ph2Sn(SBoVa) | −11.07 | 0.03 | −11.04 | −1.86 | 1.79 | −1.86 | −9.25 | −38.70 |
| Me2Sn(SBoVa) | −10.58 | −0.01 | −10.59 | −0.54 | 1.19 | −0.54 | −9.40 | −39.33 |
Figure 9(a) Schematic representation of organotin(IV) compounds that fit well in the grooves of the DNA strand obtained by docking simulations. The two double-stranded DNA comprise of the phosphate deoxyribose backbone with guanine (DG, red), cytosine (DC, blue), adenine (DA, pink) and thymine (DT, orange). (b) Molecular interactions of organotin(IV) compounds within the grooves of double stranded DNA residues.
Crystal data and refinement details for compounds Me2Sn(S2MoVa), Me2Sn(S4MoVa) and Me2Sn(SBoVa).
| Compound | Me2Sn(S2MoVa) | Me2Sn(S4MoVa) | Me2Sn(SBoVa) |
|---|---|---|---|
| Formula | C19H22N2O2S2Sn | C19H22N2O2S2Sn | C18H20N2O2S2Sn |
| Formula weight | 493.19 | 493.19 | 479.19 |
| Crystal colour | light-yellow | light-yellow | light-yellow |
| Crystal size/mm3 | 0.03 × 0.05 × 0.10 | 0.05 × 0.13 × 0.20 | 0.03 × 0.05 × 0.10 |
| Crystal system | Monoclinic | Triclinic | Triclinic |
| Space group |
|
|
|
| 11.3716(9) | 10.5908(4) | 8.9408(4) | |
| 12.0262(8) | 13.9243(5) | 10.4182(4) | |
| 16.3644(15) | 14.3974(5) | 22.6034(12) | |
| 90 | 95.596(3) | 97.713(4) | |
| 109.285(9) | 93.693(3) | 94.600(4) | |
| 90 | 102.116(2) | 111.634(4) | |
| 2112.4(3) | 2058.11(13) | 1920.11(16) | |
|
| 4 | 4 | 4 |
| 1.551 | 1.592 | 1.658 | |
| 992 | 992 | 960 | |
| μ(Mo | 1.422 | 1.46 | 1.562 |
| Measured data | 6348 | 18090 | 15229 |
| θ range/° | 3.6–29.4 | 3.5–29.4 | 3.4–29.4 |
| Unique data | 6348 | 9402 | 8720 |
| Observed data ( | 5090 | 7605 | 6671 |
| No. parameters | 478 | 477 | 457 |
| 0.037; 0.064 | 0.034; 0.070 | 0.041; 0.083 | |
| 0.022; 0 | 0.026; 0.240 | 0.032; 0.781 | |
| 0.055; 0.074 | 0.049; 0.078 | 0.062; 0.092 | |
| GoF | 0.99 | 1.01 | 1.01 |
| Range of residual electron | |||
| density peaks/eÅ−3 | −0.56–0.66 | −0.46–0.75 | −1.03–0.63 |